MOSCOW, Sept 27 (Reuters) - A small-scale clinical study of
the combined use of the AstraZeneca and Sputnik Light vaccines
against COVID-19 has shown strong antibody growth in a majority
of the study's participants, the Russian Direct Investment Fund
said on Monday.
The data was collected from 20 people who took part in a
100-person study in Azerbaijan that began in February. They
first received the AstraZeneca shot followed by the one-dose
Russian-made Sputnik Light shot 29 days later, RDIF said.
"According to the results of the interim analysis, a
fourfold or higher increase in neutralising antibodies to the
spike protein (S-protein) of the SARS-CoV-2 was found in 85% of
the volunteers on the 57th day of the study," RDIF said.
(Reporting by Maxim Rodionov; Writing by Alexander Marrow;
Editing by Louise Heavens)
Astrazeneca (AZN)
